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Background & Aims:
Patients with familial adenomatous polyposis (FAP) have a high prevalence of duodenal adenomas, and the region of the ampulla of Vater is the predilection site for duodenal adenocarcinomas. This study assessed the risk of stage IV periampullary adenomas according to the Spigelman classification and periampullary adenocarcinomas in Swedish FAP patients screened by esophagogastroduodenoscopy (EGD). The genotype of patients with stage IV periampullary adenomas and periampullary adenocarcinomas was also investigated. Methods: A retrospective study of 180 patients screened by EGD in 1982-1999 was undertaken. Kaplan-Meier analysis was performed to evaluate cumulative risk. Mutation analysis was carried out in patients with periampullary adenocarcinomas diagnosed outside the screening program, in addition to patients in the screening group with stage IV periampullary adenomas and adenocarcinomas. Results: Periampullary adenoma stage IV was diagnosed in 14 patients (7.8%), with a cumulative risk of 20% at age 60 years. Periampullary adenocarcinoma was diagnosed in 5 patients (2.8%), with a cumulative risk of 10% at age 60. Three of the adenocarcinomas occurred in patients with stage IV periampullary adenomas compared with 2 in patients with less severe periampullary adenomatosis at screening (odds ratio, 31; 95% confidence interval, 4.6 -215). Fifteen (88%) of the APC gene mutations were detected; 12 of these were located downstream from codon 1051 in exon 15 . Conclusions: The life time risk of severe periampullary lesions in FAP patients is high, and an association between stage IV periampullary adenomas and a malignant course of the periampullary adenomatosis is strongly suggestive. Mutations downstream from codon 1051 seem to be associated with severe periampullary lesions. F amilial adenomatous polyposis (FAP) is an inherited autosomal dominant disease. The gene locus is on chromosome 5q21. [1] [2] [3] The disease is characterized by the formation of adenomatous polyps in the small and large intestine and is associated with a virtual 100% risk of colorectal cancer. Prophylactic colectomy and proctocolectomy have dramatically reduced the morbidity and mortality in colorectal cancer. 4, 5 However, patients remain at risk of developing duodenal cancer which, together with desmoid tumours, currently is the main cause of FAP-related death in adequately treated patients. 6 The most common endoscopic feature of the duodenum is multiple small sessile polyps in the descending part, but some patients develop larger adenomatous polyps, often in the region of the ampulla of Vater. Moreover, the adenocarcinomas frequently occur in the ampulla region. 7 Because of the risk of life-threatening duodenal cancer, regular endoscopic follow-up is recommended, although the efficacy of screening has not yet been fully elucidated. 6, 8, 9 A genotype-phenotype correlation, i.e., that the specific germ-line mutation of the adenomatous polyposis coli (APC) gene predicts the clinical course of the disease, has been shown to exist for some features of FAP, such as the attenuated phenotype. 10 However, there has still been no satisfactory investigation of whether there is any correlation between the genotype and stage IV periampullary adenomas and periampullary adenocarcinomas. 11, 12 The aims of this study were to investigate the prevalence and cumulative risk of duodenal stage IV periampullary adenomas and periampullary adenocarcinomas in the Swedish FAP population screened by esophagogastroduodenoscopy (EGD) and to identify the germline APC gene mutations in the FAP families with a history of severe periampullary lesions.
Patients and Methods

Patients
The Swedish Polyposis Registry includes data on 467 patients with verified FAP from 154 Swedish FAP-families registered since the late 1950s. 5 One hundred ten of the patients were dead before introduction of EGD surveillance, and another 62 were not screened because at the end of the study period they were younger than 30 years old, the recommended starting age for screening in Sweden. Thus, 265 patients remained, and the registry had EGD surveillance information for 180 (68%) of these patients (88 male, 92 female) representing 79 FAP families. All patients were asymptomatic when they entered the screening program, and there was no selection of patients based on family history. The reason for EGD surveillance was the known risk of duodenal adenomas. The study period was from the introduction of screening in 1982 through the end of 1999. A total of 537 examinations were performed. The median number of examinations per patient was 2 (range, . The mean period during which EGD was performed was 72 (range, 4 -210) months. Observation time was from birth through the date of last endoscopy or diagnosis of duodenal adenomas, Spigelman stage IV periampullary adenomas, or periampullary adenocarcinomas. In addition to endoscopy reports, information was obtained from medical records, including surgical and autopsy reports. The examinations were performed at several sites in Sweden, and the results of the endoscopy and histopathologic evaluation were reported to the Swedish Polyposis Registry. Standard forward-viewing endoscopes were used. Polypectomy for severe adenomatosis outside the periampullary region was performed in only 2 patients, and major surgery (pancreaticoduodenectomy or duodenctomy) was not performed in any patients except for those accounted for in Table 1 .
The patients with diagnoses of stage IV periampullary adenomas and/or periampullary adenocarcinomas in the screening group were selected for mutation analysis. The germline APC gene mutation was able to be detected for all but 1 patient with stage IV periampullary adenomas (not found) and for all but 1 of 4 patients with periampullary adenocarcinomas (refused testing). We also included 5 patients outside the screening program who had verified periampullary adenocar- cinomas and had been reported to the registry since the first case was diagnosed in 1976. The germline APC gene mutation was identified in 3 of these patients (one could not be analyzed because there was nobody alive with FAP in the family, and one mutation was not found). All patients, except 2 siblings who developed periampullary carcinomas, belonged to different families. Mutation analysis data were also available for 25 Swedish FAP families without evidence of stage IV periampullary adenomas or a history of duodenal cancer.
Histopathology
Biopsy specimens were taken from polyps, including those in the region of ampulla of Vater when it appeared abnormal. Histopathologic diagnosis was also obtained from surgical specimens taken from patients undergoing surgery. The Spigelman classification was used to classify the periampullary adenomas (Table 2 ). 9 Only adenomas fulfilling the criteria of Spigelman stage IV were included: number, 1 (score 1); size, Ͼ10 mm (score 3); histology, tubulovillous (score 2) or villous (score 3); dysplasia, high grade (score 3).
Molecular Genetic Analyses
Genomic DNA was isolated from EDTA-treated blood with the Purgene DNA isolation kit (Gentra Systems, Minneapolis, MN) using standard methods. RNA was isolated from peripheral blood lymphocytes. Histopaque (Sigma, St. Louis, MO) was used for purification of lymphocytes, and total RNA was extracted using RNAstat 60 (Tel-Test, Friendswood, TX).
Polymerase chain reaction and reverse-transcription polymerase chain reaction. Complementary DNA (cDNA) was synthesized with 2-3 g total RNA using random primers and 200 U Superscript II reverse transcriptase according to the manufacturer's protocol (Gibco/BRL, Gaithersburg, MD). The APC gene was amplified in a total of 6 fragments. Exons 1-14 were amplified using a nested reversetranscription polymerase chain reaction (RT-PCR) approach in 2 amplicons. Primers used were described by Prosser et al. 13 Exon 15 was amplified in 4 fragments using genomic DNA as the template. Two primer pairs covering codons 1038 -1700 were described by Van der Luijt et al., 14 and two new primer pairs were designed covering the 3Ј part of the APC gene:
APC-5* fp 5Ј-CAG GAA AAT GAC AAT GGG AAT GA-3Ј APC-5* rp 5Ј-TAG GGC TTT TGG AGG CTG GAG TCT-3Ј APC-6* fp 5Ј-TCA CAG GGA GAA CCA AGT AAA CC-3Ј APC-6* rp 5Ј-GTG CCT CCC AAA ATA AGA CCA GTG -3Ј
Primer pair APC-5* included codons 1528 -2261, and primer pair APC-6* included codons 1994 -2907. All forward primers used in these reactions were flanked by a 5Ј sequence containing the T7-promotor and a eukaryotic translation initiation sequence (5Ј-GGATCCTAATACGACTCACTATAG-GAACAGACCACCA-TG-3Ј). Protein truncation test (PTT) analyses were carried out by addition of 200 -400 ng of the PCR product to the TNT Quick Coupled Transcription/Translation System (Promega, Madison, WI), 10 Ci 35 S-methionine was incorporated, and the reactions were carried out according to protocol. The synthesized protein products were analyzed using the Protean II electrophoretic separation cell (BioRad Laboratories, Hercules, CA). Homogenous 12.5% Ready-Gels (BioRad) were used as gel matrix, and the separation was performed according to the manufacturer's recommendation. Gels were fixated, dried, and exposed to radiographic film.
To conclude the locations of the mutations detected by PTT, a combined approach of single-stranded conformation polymorphism (SSCP) and heteroduplex (HD) analyses was used. For PCR, genomic DNA was amplified using primers flanking exons 1-14 and the 5Ј half of exon 15 as described by Miyoshi et al. 15 Electrophoretic separation. For denaturation, 2 L of the PCR reaction mixture was mixed with 6 L of formamide-dye solution (98% formamide, 20 mmol/L EDTA, 0.05% bromphenol blue, and 0.05% xylene cyanole). The samples were heated at 98°C for 5 minutes and then immediately put on ice. HD/SSCP analyses were performed using the Phast system (Amersham Pharmacia Biotech, Uppsala, Sweden) with a subsequent automated silver staining step for visualization of DNA fragments. Native buffer strips equilibrated (overnight) in a 0.2 mol/L Tris-Tricine buffer, pH 8.3, and homogenous 20% polyacrylamide Phast gels were used to perform the electrophoretic separation.
All mutations were verified by DNA sequence determination from both the 5Ј and 3Ј directions. Cycle sequencing was performed using the ABI Prism Big Dye Terminator Cycle Sequencing Ready Reaction Kit on the ABI 310 automated sequencer (PE Biosystems, Foster City, CA). PCR was carried out in the same way as for the SSCP/HD analyses using the same PCR primers. These fragments were used as template in the sequencing reactions. Forward and reverse primers were used as sequencing primers.
Statistical Analyses
Survival analysis was performed using the KaplanMeier method. The Fisher exact test was used for categorical data. Results are presented as odds ratios, and the variability of the data is presented as 95% confidence intervals (95% CIs).
Results
Duodenal Adenomas
Duodenal adenomas were found in 134 (74%) of the FAP patients. As shown in Figure 1 , the cumulative age-dependent risks of duodenal adenomatosis were 80% (95% CI, 72.9 -87.1) and 98% (95% CI, 95-100) at ages 60 and 75 years, respectively.
Stage IV Periampullary Adenomas
As shown in Table 1 , stage IV periampullary adenomas were found in 14 patients (7.8%): 11 at screening gastroduodenoscopy (cases 1-8 and 11-13), 1 at gastroduodenoscopy performed because of symptoms (case 14) , and 2 at surgery (cases 9 and 10). The reasons for surgery in these 2 patients were histopathology (case 9) and histopathology combined with alkaline phosphatase elevation (case 10). The time course for the development of stage IV periampullary adenomas stage IV from normal duodenum could be evaluated for 7 patients and was 7.1 (range, 5.3-9.8) years. The median age at detection was 50 (range, 32-64) years, and the cumulative age-dependent risk was 20% (95% CI, 9.7-30.3) at age 60 years (Figure 1 ). The 5 patients who did not undergo surgery had a median follow-up time of 7 (range, 4.5-10.5) years. One patient developed symptoms. Local resection of the ampulla region was performed in 4 patients (cases 6, 7, 12, and 15), and neoplastic recurrence, leading to major surgery, occurred in 2 of the patients (cases 12 and 15; Table 1 ). One patient died of disseminated rectal cancer (case 1), and 1 died of an infection (case 8).
Periampullary Adenocarcinomas
Periampullary adenocarcinomas were diagnosed in 5 patients in the screening program (2.8%), of whom 3 had a previous diagnosis of stage IV periampullary adenoma at EGD screening (cases 11-13) and 2 had less severe periampullary adenomatosis (cases 14 and 15) at screening. Thus, 3 of 11 patients in the subgroup who already had stage IV periampullary adenomas at screening endoscopy later had adenocarcinomas diagnosed, compared with 2 of 169 patients without stage IV periampullary adenomas (odds ratio, 31; 95% CI, 4.6 -215; P Յ 0.003). None of the adenocarcinomas were diagnosed during EGD screening. One was diagnosed at EGD performed because of symptoms (case 15), and 4, 3 of which had symptoms, were diagnosed at surgery (cases 
11-14)
. Last screening gastroduodenoscopy was performed a median of 16 (range, 4 -31) months before detection of cancer, and EGD or duodenoscopy because of symptoms (n ϭ 4) was performed at a median of 2.5 (range, 1-10) months before surgery. The time course for the development of periampullary adenocarcinoma from stage IV periampullary adenomas (n ϭ 4) was 3.6 (range, 0.5-9) years. The median age at diagnosis of cancer was 50 (range, 44 -57) years, and the cumulative age-dependent risk of developing cancer was 10% (95% CI, 1.0 -19.0) at age 60 years ( Figure 1) . Two patients died of disseminated periampullary adenocarcinoma (cases 12 and 14), and the median postoperative follow-up time of the 3 patients who were still alive at the end of the study period was 5.1 (range, 1.5-11.1) years. Two patients developed periampullary cancer 3 and 4 years after local resection of the periampullary lesion (cases 12 and 15, respectively).
The 5 patients outside the screening group with periampullary adenocarcinomas (cases 16 -20) had a median age at diagnosis of cancer of 55 (range, 39 -58) years. All periampullary adenocarcinomas were diagnosed because of symptoms. Two of the cases were diagnosed in the 1970s (cases 18 and 20), i.e., before the introduction of endoscopic screening, but it is more important that the remaining 3 patients, although symptoms led to diagnosis in the 1990s, had not been screened. Four patients died within 1 year after diagnosis, and the postoperative follow-up time of the only patient alive at the end of the study (case 17) was 2 years.
In summary, 9 of the 10 cases of periampullary adenocarcinomas were diagnosed because of symptoms, and 6 of these patients died during follow-up. Adenocarcinomas were not found at other sites of the duodenum, either in the screening group or in other FAP patients reported to the registry.
APC Gene Mutations
Fifteen (88.2%) of 17 mutations were identified in the families accessible for analysis. As shown in Table  3 the germline mutation was found in 9 of the 10 families with stage IV periampullary adenomas that were available for analysis, and all had different mutations. The mutations were located in 3 different regions of the APC gene: near the 5Ј end at codon 262 and 283 in exons 7 and 8, respectively, in the region from codon 1061 to codon 1170 in exon 15, and at codon 1533. Six of the mutations were frameshift mutations with 1-5 base pair deletions or insertions, and 3 were base substitutions, both causing premature stop codons. Five of these germline mutations have not been described elsewhere (codons 262, 1083, 1120, 1170, and 1533).
The germline APC mutation was identified in 6 of 7 families accessible for analysis with a history of periampullary carcinomas. The mutations were located from codon 728 to codon 1556 in exon 15, and 5 of these were located downstream from codon 1051. All of the identified mutations were frameshift mutations with 1-86 base pair deletions or insertions, causing premature stop codons. Four not previously reported mutations were identified (codons 728, 1051, 1246, and 1556). Figure 2A shows the distribution of the germline APC mutations that we found in the families with stage IV periampullary adenomas and periampullary adenocarcinomas in relation to reported germline APC gene mutations in FAP families worldwide.
The distribution of the Swedish germline APC mutations identified so far are illustrated in Figure 2B . Eighty percent (12 of 15) of the mutations in the families with a history of stage IV periampullary adenomas or periampullary adenocarcinomas were located downstream from codon 1051 in exon 15, compared with 40% (10 of 25) of the mutations in families without evidence of severe periampullary lesions (odds ratio, 6.0; 95% CI, 1.34 -26.8; P Յ 0.03). In a comparison of Figure 2A and B, no obvious difference in the distribution of mutations along the APC gene is observed between Swedish and nonSwedish FAP families. However, 38% of the mutations plotted in Figure 2B have been found in families selected for analysis because of severe periampullary lesions.
Discussion
We found that 74% of the FAP patients screened by upper endoscopy had duodenal adenomas, compared with the 33%-92% reported in previous studies of 100 or more patients. 8,16 -19 However, the cumulative risk in our material was almost 100% at the age of 75 years, indicating that all FAP patients eventually develop duodenal adenomas. The malignant potential of the most common lesions of the duodenum, the sessile adenomatous polyps predominantly located at the mucosal folds, seems to be low. This is further supported by the absence of duodenal adenocarcinomas outside the periampullary region in our material. The occurrence of dysplasia in the periampullary region has been reported by St. Mark's Hospital and the Cleveland Clinic Foundation to be as high as 74% and 66%, respectively. 8, 19 In this study we have focused on advanced periampullary adenomas classified as Spigelman stage IV because there are observations indicating that the adenomas in the periampullary region are more likely to become malignant. 7, 20 Stage IV periampullary adenomas were found in 7.8% of the endoscopically screened Swedish FAP patients, and the cumulative risk was as high as 20% at age 60 years. We also found that the cumulative risk of periampullary adenocarcinoma was 10% at age 60 years. This is higher than that of a previous northern European study in which the cumulative risk was estimated to be 3%-4% at age 70 years. 21 However, the absence of age distribution data and data on prophylactic surgery makes it difficult to compare different studies. There were no reports of periampullary adenocarcinoma in the Swedish registry before 1976, and 7 of 9 cases occurred within the last 10-year period of the study, indicating that periampullary adenocarcinoma might become an increasing clinical problem. One possible explanation for the low incidence of periampullary carcinomas before the 1990s is that previous FAP generations died with colorectal cancer at a younger age in which duodenal cancer was unlikely to occur.
Our results also indicate that despite endoscopic follow-up, there is a risk of death caused by periampullary adenocarcinoma. A more detailed analysis also shows that upper endoscopy, including biopsies of the lesion, is of poor diagnostic value in the detection of periampullary adenocarcinoma because only 2 (29%) of 7 patients in the symptomatic phase were diagnosed with cancer even though they were all endoscopically examined close to surgery. In a recent study, the corresponding figure was 32%, supporting the finding that random biopsies from the surface of the lesion are not sufficient for cancer detection. 22 Despite this conclusion, our data indicate that patients with stage IV periampullary adenomas diagnosed by upper endoscopy run a much higher risk of developing periampullary adenocarcinomas than those without evidence of stage IV periampullary adenomas, identification of these lesions seems useful. Therefore, FAP patients should undergo endoscopic surveys at frequent intervals 8 because endoscopy is currently the only screening technique available. Forward-viewing instruments do not always permit optimal visualization of the periampullary region, and side-viewing instruments allow better biopsy precision when the lesion has been recognized. Therefore, the use of side-viewing instruments may improve yields. The benefit of prophylactic surgery is still not clear, but surgical treatment must be considered in severe cases of duodenal adenomatosis. 8, 9, 21, 23, 24 In our material, the recurrence rate after local excision of stage IV periampullary adenomas was high, and more extensive surgery was required. When cholestasis or other local symptoms occurred, all but 1 already had cancer and, despite immediate extensive surgery, the prognosis was poor.
We found that most germline APC mutations in this selected material of FAP families with severe periampullary lesions were located within relatively restricted regions of the APC gene. All but 2 mutations were identified and indicate that chain-terminating mutations might be a prerequisite for severe periampullary lesions. The high sensitivity compared with most other studies is probably an effect of the phenotype selected for this study. Studies on genotype-phenotype correlation have often shown that there is not only a wide genetic heterogeneity but also phenotypic heterogeneity both within a family and between families with mutations in a similar region of the APC gene. [25] [26] [27] However, the APC gene mutations in families with a history of sparse polyposis and late-onset colorectal cancer (attenuated FAP) are located at the proximal 5Ј end or in the 3Ј end of the APC gene. 10, 28 It has still not been fully clarified whether the genotype can predict the course of the periampullary adenomatosis. A previous study found no correlation between detectable germline APC mutations and the frequency and severity of the periampullary adenomatosis. 11 Another study on genotype-phenotype correlation including 3 cases of periampullary adenocarcinomas showed no correlation, although all periampullary adenocarcinomas were located downstream from exon 10 (codon 457). 12 The clustering of APC mutations downstream from codon 1051 in our families with a history of severe periampullary lesions indicates that mutations in this region of exon 15, containing the 2 most common germline deletion hot spots of the APC (codon 1061 and 1309), might be associated with an increased risk of stage IV periampullary adenomas and periampullary adenocarcinomas. Further supporting this observation is the more disseminated distribution along the APC gene of the mutations observed in Swedish FAP families with-out evidence of severe periampullary lesions. However, because a minority of Swedish FAP families have been tested, the results so far cannot rule out the possibility that the clustering of the mutations in families with severe duodenal lesions is attributed to a relative homogeneity of the Swedish population.
The region of the APC protein corresponding to the region where most mutations are clustered contains 3 15-amino acid repeats that associate with the multifunctional protein known as ␤-catenin. Impaired binding causes accumulation of ␤-catenin in the cytoplasm that could cause dysregulation of several vital cell functions such as transcription, cell cycle regulation, migration, differentiation, and apoptosis. 26 A previous study described a family with a mutation at codon 1520 and severe duodenal adenomatosis, 27 and our only family with 2 members with periampullary carcinomas had the APC mutation at codon 1556, corresponding to a region of the APC protein with 20 -amino acid repeats that interact with ␤-catenin and mediate its down-regulation, 28 providing further evidence of a possible correlation between a severe course of the periampullary adenomatosis and mutations in the region of the APC gene encoding for ␤-catenin-regulating properties.
The detection rate of mutation analyses, covering the entire coding region, in identification of the mutations in different FAP populations is not entirely satisfactory, varying between 44% and 72% in recent studies. [32] [33] [34] [35] In this study, we have used both DNA-and mRNA-based analyses, a method that has been shown to be a prerequisite for high-quality mutation analyses of the APC gene. [13] [14] [15] 36 In conclusion, periampullary adenocarcinomas are an increasing clinical problem in the FAP population in countries where the screening and treatment of colorectal cancer is efficient. Endoscopic screening, including extensive biopsies of the periampullary region for histopathologic evaluation, is essential, and stage IV periampullary adenomas must be taken seriously because our results further support the accepted hypothesis of adenoma-carcinoma progression. The region downstream from codon 1051 in exon 15 of the APC gene seems to be associated with severe duodenal lesions. Thus, genetic screening might be used to predict the outcome of the duodenal adenomatosis in FAP families and to provide guidance in terms of surveillance and treatment.
